《立体定向放射治疗难治性室性心动过速》

  • 来源专题:心血管疾病防治
  • 编译者: 张燕舞
  • 发布时间:2018-05-22
  • 临床前研究和病例报告表明立体定向放射治疗在一些恶性肿瘤的治疗中很有效,可能对难治性室性心动过速(VT)有效。 在一个单中心病例系列研究中,5例患有先前射频消融失败的结构性心脏病患者(或者不是消融候选者)以及持续性VT,尽管有两种或更多种抗心律失常药物,但立体定向放射治疗可以减少过多的VT负荷 99%,一般耐受性良好。 鉴于患者人群室性心律失常的减少程度有限,而其他治疗方案有限,立体定向放射治疗是一种潜在的有吸引力的治疗方法,但在更大规模的研究中需要额外的有效性和安全性评估。

    BACKGROUND Recent advances have enabled noninvasive mapping of cardiac arrhythmias with electrocardiographic imaging and noninvasive delivery of precise ablative radiation with stereotactic body radiation therapy (SBRT). We combined these techniques to perform catheter-free, electrophysiology-guided, noninvasive cardiac radioablation for ventricular tachycardia.

    METHODS We targeted arrhythmogenic scar regions by combining anatomical imaging with noninvasive electrocardiographic imaging during ventricular tachycardia that was induced by means of an implantable cardioverter-defibrillator (ICD). SBRT simulation, planning, and treatments were performed with the use of standard techniques. Patients were treated with a single fraction of 25 Gy while awake. Efficacy was assessed by counting episodes of ventricular tachycardia, as recorded by ICDs. Safety was assessed by means ofserial cardiac and thoracic imaging.

    RESULTS From April through November 2015, five patients with high-risk, refractory ventricular tachycardia underwent treatment. The mean noninvasive ablation time was 14 minutes (range, 11 to 18). During the 3 months before treatment, the patients had a combined history of 6577 episodes of ventricular tachycardia. During a 6-week postablation "blanking period" (when arrhythmias may occur owing to postablation inflammation), there were 680 episodes of ventricular tachycardia. After the 6-week blanking period, there were 4 episodes of ventricular tachycardia over the next 46 patient-months, for a reduction from baseline of 99.9%. A reduction in episodes of ventricular tachycardia occurred in all five patients. The mean left ventricular ejection fraction did not decrease with treatment. At 3 months, adjacent lung showed opacities consistent with mild inflammatory changes, which had resolved by 1 year.

    CONCLUSIONS In five patients with refractory ventricular tachycardia, noninvasive treatment with electrophysiology-guided cardiac radioablation markedly reduced the burden of ventricular tachycardia. (Funded by Barnes-Jewish Hospital Foundation and others.).

相关报告
  • 《Nature | 共价靶向放射性配体增强放射性核素治疗》

    • 编译者:李康音
    • 发布时间:2024-05-26
    • 2024年5月22日,北京大学/昌平实验室刘志博教授团队在 Nature 期刊发表了题为Covalent Targeted Radioligands Potentiate Radionuclide Therapy 的研究论文。 常用治疗放射性核素的半衰期可达3到10天。因此,理想的治疗性放射配体需满足优异的肿瘤靶向、足够的肿瘤滞留和快速的正常器官清除。然而,如何平衡药物的血液清除和肿瘤滞留一直是药物设计中的经典难题之一。由于配体-靶点间常为可逆相互作用,传统低分子量放射配体的肿瘤滞留通常不足,大大制约了TRT的疗效。若能开发出一种平台技术,将放射配体以肿瘤选择性的方式不可逆地固定到癌症靶标上,将是解决上述问题的理想方案。 研究团队基于现代共价药物分子工程,发展了一类新的药物形式——靶向共价放射配体(Covalent Targeted Radioligand,CTR),并从分子、细胞、小鼠及患者层面验证了该平台技术的有效性,突破了成纤维细胞活化蛋白(FAP,为泛癌种靶点)靶向放射配体因肿瘤摄取、滞留不足导致疗效不佳的瓶颈,初步实现了上文提及的理想方案。据了解,这是 Nature 杂志自1977年以来首次发表核素治疗相关的工作。
  • 《Obiltoxaximab获批用于吸入性炭疽的治疗及预防性治疗》

    • 来源专题:重大新药创制—研发动态
    • 编译者:杜慧
    • 发布时间:2016-04-18
    • Obiltoxaximab (Anthim®,ETI 204)是一种单克隆抗体,由Elusys Therapeutics公司开发,获批用于吸入性炭疽的治疗及预防性治疗。Obiltoxaximab可以中和炭疽杆菌的保护性抗原,从而抑制炭疽毒素的致命作用。2016 年 3 月,FDA批准obiltoxaximab静脉注射给药(与适当的抗菌药物联合用药)用于吸入性炭疽的治疗及预防性治疗。obiltoxaximab的获批,是基于动物试验的疗效数据及健康受试者I期安全性研究数据。此外,动物试验和I期临床试验也对obiltoxaximab的肌肉注射液制剂进行了评估。